Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men

Details

• Alternative Title:
  J Antimicrob Chemother
• Personal Author:
  Haaland, Richard E. ; Fountain, Jeffrey ; Martin, Amy ; Dinh, Chuong ; Holder, Angela ; Edwards, Tiancheng E. ; Lupo, L. Davis ; Hall, LaShonda ; Conway-Washington, Christopher ; Massud, Ivana ; García-Lerma, J. Gerardo ; Kelley, Colleen F. ; Heneine, Walid M.
• Description:
  Background:
  
  Event-driven HIV prevention strategies are a priority for users who do not require daily pre-exposure prophylaxis (PrEP). Regimens containing integrase strand transfer inhibitors (INSTIs) are under evaluation as alternatives to daily PrEP. To better understand INSTI distribution and inform dosing selection we compared the pharmacology of two-dose boosted elvitegravir and unboosted bictegravir regimens in MSM.
  
  Materials and methods:
  
  Blood, rectal and penile secretions and rectal biopsies were collected from 63 HIV-negative MSM aged 18–49 years. Specimens were collected up to 96 h after two oral doses of tenofovir alafenamide and emtricitabine with elvitegravir boosted by cobicistat or unboosted bictegravir given 24 h apart. Antiretroviral drugs were measured by LC-MS.
  
  Results:
  
  Mean bictegravir plasma concentrations remained above the 95% protein-adjusted effective concentration 96 h after dosing [273 (95% CI: 164–456) ng/mL] whereas elvitegravir plasma concentrations became undetectable 48 h after the second dose. Bictegravir and elvitegravir reached rectal tissues within 2 h after the first dose, and elvitegravir tissue concentrations [1.07 (0.38–13.51) ng/mg] were greater than bictegravir concentrations [0.27 (0.15–0.70) ng/mg]. Both INSTIs became undetectable in tissues within 96 h. Elvitegravir and bictegravir were not consistently detected in penile secretions.
  
  Conclusions:
  
  Whereas bictegravir plasma concentrations persist at least 4 days after a two-oral-dose HIV prophylaxis regimen, elvitegravir accumulates in mucosal tissues. Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention.
  
  
• Keywords:
  Adolescent Adult Anti-HIV Agents Emtricitabine Heterocyclic Compounds, 3-Ring HIV Infections HIV Integrase Inhibitors Homosexuality, Male Humans Integrases Male Middle Aged Pyridones Sexual And Gender Minorities Young Adult

  More +
• Source:
  J Antimicrob Chemother. 78(2):497-503
• Pubmed ID:
  36512383
• Pubmed Central ID:
  PMC10161260
• Document Type:
  Journal Article
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  78
• Issue:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:4c05f8f02199ecfb86e585758c2043f067864e2bb60736b618fe253e8b1bc8d5
• Download URL:
  https://stacks.cdc.gov/view/cdc/127863/cdc_127863_DS1.pdf
• File Type:
  [PDF - 591.78 KB ]